• Publications
  • Influence
Global strategy for asthma management and prevention: GINA executive summary
TLDR
It is reasonable to expect that in most patients with asthma, control of the disease can and should be achieved and maintained, and the Global Initiative for Asthma recommends a change in approach to asthma management, with asthma control, rather than asthma severity, being the focus of treatment decisions. Expand
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
TLDR
Recommendations and guidelines on the evaluation and treatment of severe asthma in children and adults and coordinated research efforts for improved phenotyping will provide safe and effective biomarker-driven approaches to severe asthma therapy are provided. Expand
Asthma phenotypes: the evolution from clinical to molecular approaches
TLDR
Ongoing studies of large-scale, molecularly and genetically focused and extensively clinically characterized cohorts of asthma should enhance the ability to molecularly understand these phenotypes and lead to more targeted and personalized approaches to asthma therapy. Expand
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.
TLDR
Five distinct clinical phenotypes of asthma have been identified using an unsupervised hierarchical cluster analysis, which supports clinical heterogeneity in asthma and the need for new approaches for the classification of disease severity in asthma. Expand
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.
TLDR
New definitions for asthma control, severity, and exacerbations are developed, based on current treatment principles and clinical and research relevance, to provide a basis for a multicomponent assessment of asthma by clinicians, researchers, and other relevant groups in the design, conduct, and evaluation of clinical trials, and in clinical practice. Expand
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
TLDR
In patients requiring daily oral glucocorticoid therapy to maintain asthma control, mepolizumab had a significant glucoc Corticoid-sparing effect, reduced exacerbations, and improved control of asthma symptoms. Expand
Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics.
TLDR
The results suggest that two distinct pathologic, physiologic, and clinical subtypes of severe asthma exist, with implications for further research and treatment. Expand
Asthma: defining of the persistent adult phenotypes
TLDR
This Review analyses some of the methods that have been used to define asthma phenotypes and proposes an integrated method of classification to improve the understanding of these phenotypes. Expand
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome.
TLDR
Criteria for defining asthma endotypes on the basis of their phenotypes and putative pathophysiology are suggested and how these new definitions can be used in clinical study design and drug development to target existing and novel therapies to patients most likely to benefit are proposed. Expand
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind
TLDR
This clinical trial aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist, irrespective of baseline eosinophil count. Expand
...
1
2
3
4
5
...